{"denoms":[{"counts":[{"groupId":"BG000","value":"317"},{"groupId":"BG001","value":"317"},{"groupId":"BG002","value":"350"},{"groupId":"BG003","value":"351"},{"groupId":"BG004","value":"350"},{"groupId":"BG005","value":"349"},{"groupId":"BG006","value":"2034"}],"units":"Participants"}],"groups":[{"description":"Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 130 mg/m\\^2 over 2 hours on Day 1 of every 3 weeks before the first dose of capecitabine. Capecitabine was administered orally within 30 minutes after the end of a meal (breakfast and dinner) at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG000","title":"Xelox"},{"description":"Participants in the 2-arm part of the study received intravenous infusion of oxaliplatin 85 mg/m\\^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m\\^2 iv for 2 hours followed by fluorouracil 400 mg/m\\^2 bolus injection over 2 to 4 min followed by 600 mg/m\\^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG001","title":"Folfox-4"},{"description":"Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for bevacizumab (BV) \\[volume equivalent to 7.5 mg/kg BV\\] over 30 to 90 minutes followed by oxaliplatin 130 mg/m\\^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG002","title":"Xelox+P"},{"description":"Participants in the 2x2 factorial part of the study received intravenous infusion of placebo control for BV (volume equivalent to 5 mg/kg BV) over 30 to 90 minutes followed by oxaliplatin 85 mg/m\\^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m\\^2 iv for 2 hours followed by fluorouracil 400 mg/m\\^2 bolus injection over 2 to 4 min followed by 600 mg/m\\^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG003","title":"Folfox-4+P"},{"description":"Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 7.5 mg/kg over 30 to 90 minutes followed by oxaliplatin 130 mg/m\\^2 over 2 hours on Day 1 of every 3 weeks in combination with capecitabine, administered orally at a dose of 1000 mg/m\\^2 twice-daily (equivalent to a total daily dose of 2000 mg/m\\^2), for the first 2 weeks of every 3-week cycle. Participants received up to 16 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG004","title":"Xelox+BV"},{"description":"Participants in the 2x2 factorial part of the study received intravenous infusion of bevacizumab 5 mg/kg over 30 to 90 minutes followed by oxaliplatin 85 mg/m\\^2 on Day 1 of every 2-week cycle; concomitantly with leucovorin 200 mg/m\\^2 iv for 2 hours followed by fluorouracil 400 mg/m\\^2 bolus injection over 2 to 4 min followed by 600 mg/m\\^2 continuous infusion over 22 h on Days 1 and 2 of every 2-week cycle. Participants received up to 24 cycles of treatment during the primary study treatment phase (48 weeks). Participants who completed the 48-week primary study treatment phase without progressive disease were eligible to enter the post-study treatment phase at the discretion of the investigator and the sponsor. Participants who entered this phase were to continue treatment on the same regimen to which they were initially randomized until either progression of disease was documented, unacceptable toxicity occurred, or the participant withdrew consent.","id":"BG005","title":"Folfox-4+BV"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.76","value":"60.3"},{"groupId":"BG001","spread":"10.94","value":"60.6"},{"groupId":"BG002","spread":"12.14","value":"59.1"},{"groupId":"BG003","spread":"10.87","value":"58.8"},{"groupId":"BG004","spread":"11.28","value":"59.7"},{"groupId":"BG005","spread":"10.74","value":"59.7"},{"groupId":"BG006","spread":"11.14","value":"59.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"113"},{"groupId":"BG002","value":"145"},{"groupId":"BG003","value":"165"},{"groupId":"BG004","value":"137"},{"groupId":"BG005","value":"144"},{"groupId":"BG006","value":"827"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"194"},{"groupId":"BG001","value":"204"},{"groupId":"BG002","value":"205"},{"groupId":"BG003","value":"186"},{"groupId":"BG004","value":"213"},{"groupId":"BG005","value":"205"},{"groupId":"BG006","value":"1207"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"}],"populationDescription":"Baseline characteristics were described for the Intent-to-treat (ITT) population.This population included all randomized participants who provided written informed consent."}